NRAS and melanoma: Responses to RAF265 in BRAF‐WT patients may also be associated with alternative mutations that were not systematically evaluated in this study, such as mutations in NRAS, which occur mutually exclusive from BRAF mutations in ~25% of patients, non‐V600E BRAF mutations in ~5–10% of patients, NF1 in ~10–15% of patients and PTEN loss, which is found in ~10% of melanoma and occur with or without concomitant BRAF mutation 6, 7.